电子邮件 | ema***@***.com | 获取Email |
---|
电子邮件 | ema***@***.com | 获取Email |
---|
We research and develop proprietary chemically-derived allogeneic cell therapy for degenerative diseases like Parkinson's Disease, Retinal Degenerative Diseases, Ischemic Stroke, etc. Our leading pipeline NouvNeu001 (Parkinson's Disease) is scheduled to initiate Phase I clinical trial in 2023 H1. We are a passionate team committed to developing first-in-class therapies for patients suffering from major incurable diseases. Making fast-acting and disease-reversing therapies accessible to patients in the greatest extent possible is our priority.
总部 | Wuhan, Hubei |
---|---|
行业 |
research |
公司 | iRegene Therapeutics |
---|---|
职位 | Chief Medical Officer |
地点 | United Kingdom |
http://www.linkedin.com/in/meng-cai-7451a984 | |
部门 | c_suite,medical_health |
头衔 | Research Fellow at Aston University |
Meng Cai 在 iRegene Therapeutics 担任 Research Fellow at Aston University
Meng Cai 在 iRegene Therapeutics 的职位是 Research Fellow at Aston University
Meng Cai 的电子邮件地址是 ema***@***.com
Meng Cai 的电话号码是 -
Meng Cai 的公司电话号码是 +862****
Meng Cai 在 research 工作。
Meng Cai 的一些同事包括Meng Cai、Jun Wei、Katy Huang、Emmanuel MontetRain He、。
Meng Cai联系方式: 电子邮件地址:ema***@***.com 电话号码:-
Meng Cai 的个人领英是:http://www.linkedin.com/in/meng-cai-7451a984
Meng Cai 的办公地点:Wuhan, Hubei
Top-ranked on G2 Crowd
全球B2B企业库 海关贸易数据 展会采购数据
全球B2B企业库
海关贸易数据
展销采购数据
Top-ranked on G2 Crowd